HRP20210838T1 - Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe - Google Patents
Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe Download PDFInfo
- Publication number
- HRP20210838T1 HRP20210838T1 HRP20210838TT HRP20210838T HRP20210838T1 HR P20210838 T1 HRP20210838 T1 HR P20210838T1 HR P20210838T T HRP20210838T T HR P20210838TT HR P20210838 T HRP20210838 T HR P20210838T HR P20210838 T1 HRP20210838 T1 HR P20210838T1
- Authority
- HR
- Croatia
- Prior art keywords
- lymphoma
- combination according
- hodgkin
- seq
- antibody
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 7
- 229960001183 venetoclax Drugs 0.000 claims 7
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (20)
1. Kombinacija, naznačena time, da sadrži protutijelo specifično za CD19 gdje navedeno protutijelo sadrži regiju HCDR1 koja sadrži slijed SYVMH (SEQ ID NO: 1), regiju HCDR2 koja sadrži slijed NPYNDG (SEQ ID NO: 2), regiju HCDR3 koja sadrži slijed GTYYYGTRVFDY (SEQ ID NO: 3), regiju LCDR1 koja sadrži slijed RSSKSLQNVNGNTYLY (SEQ ID NO: 4), regiju LCDR2 koja sadrži slijed RMSNLNS (SEQ ID NO: 5), i regiju LCDR3 koja sadrži slijed MQHLEYPIT (SEQ ID NO: 6) i venetoklaks za uporabu u liječenju non-Hodgkinovog limfoma, kronične limfocitne leukemije i/ili akutne limfoblastične leukemije.
2. Kombinacija u skladu s uporabom iz patentnog zahtjeva 1, naznačena time, da protutijelo ima djelovanje ADCC.
3. Kombinacija u skladu s uporabom iz patentnog zahtjeva 1 ili 2, naznačena time, da protutijelo sadrži varijabilni teški lanac koji sadrži slijed
EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGYINPY
NDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGTYYYGTRVFDYW
G QGTLVTVSS (SEQ ID NO: 10) i varijabilni laki lanac koji sadrži slijed
DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYR
MSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK
(SEQ ID NO: 11).
4. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da protutijelo sadrži konstantnu domenu teškog lanca koja sadrži slijed
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE
LLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAPEEKTISKTKGQPREPQV
YLTPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFL
YSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).
5. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da protutijelo sadrži konstantnu domenu lakog lanca koja sadrži slijed
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).
6. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da se spomenuto protutijelo koje je specifično za CD19 i venetoklaks formuliraju u različitim farmaceutskim pripravcima.
7. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da se spomenuto protutijelo koje je specifično za CD19 i venetoklaks primjenjuju odvojeno.
8. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da:
(a) venetoklaks se primjenjuje prije primjene protutijela koje je specifično za CD19; ili
(b) spomenuto protutijelo koje je specifično za CD19 se primjenjuje prije venetoklaksa.
9. Kombinacija u skladu s uporabom iz bilo kojeg od patentnih zahtjeva 1 do 6, naznačena time, da se spomenuto protutijelo koje je specifično za CD19 i venetoklaks primjenjuju istovremeno.
10. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da se spomenuto protutijelo koje je specifično za CD19 i venetoklaks primjenjuju u razdoblju kada su oba lijeka aktivna kod pacijenta u isto vrijeme.
11. Kombinacija u skladu s uporabom iz bilo kojeg od prethodnih patentnih zahtjeva, naznačena time, da je za uporabu u liječenju kronične limfocitne leukemije.
12. Kombinacija u skladu s uporabom iz bilo kojeg od patentnih zahtjeva 1 do 10, naznačena time, da je za uporabu u liječenju akutne limfoblastične leukemije.
13. Kombinacija u skladu s uporabom iz bilo kojeg od patentnih zahtjeva 1 do 10, naznačena time, da je za uporabu u liječenju non-Hodgkinovog limfoma, opcionalno gdje se non-Hodgkinov limfom bira iz skupine koja se sastoji od folikularnog limfoma, malog limfocitnog limfoma, limfoma limfnog tkiva vezanog uz sluznicu, limfoma marginalne zone, difuznog velikog limfoma B stanica, Burkittovog limfoma, i limfoma plaštenih stanica.
14. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest folikularni limfom.
15. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest mali limfocitni limfom.
16. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest limfom limfnog tkiva vezanog uz sluznicu.
17. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest limfom marginalne zone.
18. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest difuzni veliki limfom B stanice.
19. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest Burkittov limfom.
20. Kombinacija u skladu s uporabom patentnog zahtjeva 13, naznačena time, da non-Hodgkinov limfom jest limfom plaštenih stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16196184 | 2016-10-28 | ||
| EP17797564.6A EP3532098B1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
| PCT/EP2017/077654 WO2018078123A1 (en) | 2016-10-28 | 2017-10-27 | Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210838T1 true HRP20210838T1 (hr) | 2021-08-06 |
Family
ID=57218739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210838TT HRP20210838T1 (hr) | 2016-10-28 | 2021-05-25 | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20190241656A1 (hr) |
| EP (2) | EP3532098B1 (hr) |
| JP (2) | JP7094950B2 (hr) |
| KR (2) | KR102500868B1 (hr) |
| CN (2) | CN118045175A (hr) |
| AU (1) | AU2017348624A1 (hr) |
| BR (1) | BR112019008244A2 (hr) |
| CA (1) | CA3037246A1 (hr) |
| CY (1) | CY1124648T1 (hr) |
| DK (1) | DK3532098T3 (hr) |
| ES (1) | ES2871574T3 (hr) |
| HR (1) | HRP20210838T1 (hr) |
| HU (1) | HUE054496T2 (hr) |
| IL (2) | IL266216B2 (hr) |
| LT (1) | LT3532098T (hr) |
| MX (2) | MX2019004942A (hr) |
| PL (1) | PL3532098T3 (hr) |
| PT (1) | PT3532098T (hr) |
| RS (1) | RS62036B1 (hr) |
| RU (1) | RU2756405C2 (hr) |
| SG (1) | SG10202104036QA (hr) |
| SI (1) | SI3532098T1 (hr) |
| WO (1) | WO2018078123A1 (hr) |
| ZA (1) | ZA201903302B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018220040A1 (en) | 2017-05-31 | 2018-12-06 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| GB201809746D0 (en) * | 2018-06-14 | 2018-08-01 | Berlin Chemie Ag | Pharmaceutical combinations |
| EP3843748A1 (en) * | 2018-08-31 | 2021-07-07 | ADC Therapeutics SA | Combination therapy |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| CA2422076A1 (en) | 2000-09-18 | 2002-03-21 | Idec Pharmaceutical Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| JP5215180B2 (ja) | 2005-06-20 | 2013-06-19 | メダレックス インコーポレーティッド | Ｃｄ１９抗体およびその使用法 |
| EP1966245B1 (en) | 2005-12-30 | 2011-05-18 | Merck Patent GmbH | Anti-cd19 antibodies with reduced immunogenicity |
| PT2383297E (pt) | 2006-08-14 | 2013-04-15 | Xencor Inc | Anticorpos otimizados que visam cd |
| PT2066349E (pt) | 2006-09-08 | 2012-07-02 | Medimmune Llc | Anticorpos anti-cd19 humanizados e respectiva utilização no tratamento de tumores, transplantação e doenças auto-imunes |
| WO2008150494A1 (en) | 2007-05-30 | 2008-12-11 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| SI2211904T1 (sl) | 2007-10-19 | 2016-12-30 | Seattle Genetics, Inc. | CD19 vezavna sredstva in njihove uporabe |
| CA2753158A1 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| EP2445530B1 (en) | 2009-06-24 | 2016-09-07 | The Feinstein Institute for Medical Research | Method for treating chronic lymphocytic leukemia |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2013024095A1 (en) * | 2011-08-16 | 2013-02-21 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a purine analog |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| EP3476392A1 (en) * | 2014-02-28 | 2019-05-01 | Merck Sharp & Dohme Corp. | Method for treating cancer |
| EP3256493A4 (en) * | 2015-02-12 | 2018-07-11 | Seattle Genetics, Inc. | Combination therapy using a cd19-adc and vincristine |
-
2017
- 2017-10-27 EP EP17797564.6A patent/EP3532098B1/en active Active
- 2017-10-27 WO PCT/EP2017/077654 patent/WO2018078123A1/en unknown
- 2017-10-27 US US16/342,645 patent/US20190241656A1/en active Pending
- 2017-10-27 ES ES17797564T patent/ES2871574T3/es active Active
- 2017-10-27 SI SI201730811T patent/SI3532098T1/sl unknown
- 2017-10-27 CN CN202410183851.8A patent/CN118045175A/zh active Pending
- 2017-10-27 BR BR112019008244A patent/BR112019008244A2/pt unknown
- 2017-10-27 IL IL266216A patent/IL266216B2/en unknown
- 2017-10-27 RS RS20210792A patent/RS62036B1/sr unknown
- 2017-10-27 HU HUE17797564A patent/HUE054496T2/hu unknown
- 2017-10-27 AU AU2017348624A patent/AU2017348624A1/en active Pending
- 2017-10-27 IL IL301786A patent/IL301786A/en unknown
- 2017-10-27 PL PL17797564T patent/PL3532098T3/pl unknown
- 2017-10-27 PT PT177975646T patent/PT3532098T/pt unknown
- 2017-10-27 JP JP2019522273A patent/JP7094950B2/ja active Active
- 2017-10-27 KR KR1020197012532A patent/KR102500868B1/ko active IP Right Grant
- 2017-10-27 KR KR1020237005018A patent/KR20230028571A/ko not_active Application Discontinuation
- 2017-10-27 CA CA3037246A patent/CA3037246A1/en active Pending
- 2017-10-27 EP EP21165598.0A patent/EP3903821A1/en active Pending
- 2017-10-27 MX MX2019004942A patent/MX2019004942A/es unknown
- 2017-10-27 CN CN201780067047.1A patent/CN109890418B/zh active Active
- 2017-10-27 LT LTEP17797564.6T patent/LT3532098T/lt unknown
- 2017-10-27 DK DK17797564.6T patent/DK3532098T3/da active
- 2017-10-27 SG SG10202104036QA patent/SG10202104036QA/en unknown
- 2017-10-27 RU RU2019113370A patent/RU2756405C2/ru active
-
2019
- 2019-04-26 MX MX2022016270A patent/MX2022016270A/es unknown
- 2019-05-24 ZA ZA2019/03302A patent/ZA201903302B/en unknown
-
2021
- 2021-05-25 HR HRP20210838TT patent/HRP20210838T1/hr unknown
- 2021-06-10 CY CY20211100512T patent/CY1124648T1/el unknown
-
2022
- 2022-06-22 JP JP2022100006A patent/JP2022137089A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
| HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
| HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
| JP2017048208A5 (hr) | ||
| HRP20210945T1 (hr) | Formulacije protutijela anti-cd19 | |
| JP2017507954A5 (hr) | ||
| JP2017528462A5 (hr) | ||
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| AR110203A1 (es) | Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1 | |
| RU2019112029A (ru) | Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований | |
| RU2016147523A (ru) | Лечение гиперкинетических двигательных расстройств | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| JP2015529225A5 (hr) | ||
| MX2019012884A (es) | Terapia de combinacion. | |
| HRP20220224T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
| JP2019533682A5 (hr) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| JP2023093495A5 (hr) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| HRP20220228T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
| RU2018125622A (ru) | Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза | |
| AR102593A1 (es) | Anticuerpos anti-pdgf-b y métodos de uso | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases |